WS #3775

The dominant signal in this 10-minute window is the escalating energy crisis driven by Middle East geopolitical tensions, with Moody's warning that a prolonged closure of the Strait of Hormuz could push European gas prices above €100/MWh, specifically impacting Italy and Belgium due to their reliance on Qatari LNG. This corroborates earlier reports of oil price spikes and fuel shortages, with Shell's CEO predicting energy shortages in Europe from April. Concurrently, Russia is preparing a temporary gasoline export ban from April 1 to July 31 to curb domestic price spikes, which may tighten global fuel supplies and exacerbate inflationary pressures. In corporate developments, significant biopharma news includes Connect Biopharma presenting positive Phase 3 results for rademikibart in atopic dermatitis at the AAD meeting, corroborated by an 8-K filing, which could move ticker CNTB. United Therapeutics reported its TETON-1 study for nebulized Tyvaso in idiopathic pulmonary fibrosis met its primary endpoint, potentially boosting UTHR. Additionally, Sysco reaffirmed its Q3 adjusted EPS outlook of ~$0.94, indicating stability amid earlier M&A rumors, which may support SYY. Technology and regulatory updates include Microsoft forming a new team to develop native Windows apps, moving away from web-based interfaces to improve performance, which could positively impact user experience and MSFT's ecosystem. The EU approved new tariffs on low-value imports from platforms like Shein and Temu, effective soon, which may increase costs for consumers and affect e-commerce competitiveness, though no direct US tickers are immediately impacted.